Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Illegally Restricting the U.K. Seroxat Market

The U.K. Competition and Markets Authority (CMA) fined GlaxoSmithKline £37.6 million (US$53.7 million) for illegally preventing competitors from developing a generic replacement for Glaxo’s anti-depressant drug Seroxat (paroxetine). The fines cover the period 2001 to 2004, when Generics UK and Alpharma, who were seeking to enter the UK market with rival products, agreed to a “pay-for-delay” scheme with Glaxo by which the companies were paid over £50 million by Glaxo in exchange for withholding their products from the market.

Misconduct Type
Antitrust
Enforcement Agency
International
Contracting Party
None
Court Type
Administrative
Disposition
Fine
Date of Fine Announcement
2/12/2016
Contractors Involved Penalty
Total
GlaxoSmithKline $53,724,533
Further Information Released
CMA Case Information 2/12/2016
CMA Press Release 2/12/2016

Federal Contractor Misconduct Database